Ixmyelocel-T Shown to Protect Heart From Damage in Murine Model of Heart Failure
June 06 2012 - 6:00PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced results from a preclinical study demonstrating the
ability of ixmyelocel-T to protect the ischemic heart from damage
in a murine model of heart failure. Results were presented at the
18th Annual International Society for Cellular Therapy Meeting in a
poster presentation entitled "Ixmyelocel-T protects the heart from
damage in a murine model of heart failure."
In a blinded, vehicle-controlled study, a murine model of
non-acute left anterior descending (LAD) coronary artery occlusion
was used to evaluate ixmyelocel-T as a potential treatment for
dilated cardiomyopathy (DCM). Hearts were analyzed four weeks
following injection and those in the treated group experienced a
significant decrease in infarct length compared to the vehicle
control group. The results were consistent between two lots of
ixmyelocel-T (Lot 1: 2.72+/- 0.77 vs. 6.14+/- 0.43, P
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024